Polar Asset Management Partners Inc. Purchases Shares of 64,050 Trevi Therapeutics, Inc. $TRVI

Key Points

• Polar Asset Management Partners Inc. acquired 64,050 shares of Trevi Therapeutics, valued at approximately $403,000, increasing its ownership to about 0.06% of the company.
• Hedge funds and institutional investors hold approximately 95.76% of Trevi Therapeutics' stock, with multiple firms increasing their stakes recently.
• Analysts have a consensus rating of "Buy" for Trevi Therapeutics, with price targets ranging from $20.11 to $29.00 per share.

Polar Asset Management Partners Inc. acquired a new stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) during the first quarter, according to its most recent filing with the SEC. The firm acquired 64,050 shares of the company's stock, valued at approximately $403,000. Polar Asset Management Partners Inc. owned about 0.06% of Trevi Therapeutics as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the company. Millennium Management LLC boosted its position in Trevi Therapeutics by 356.3% in the 1st quarter. Millennium Management LLC now owns 823,249 shares of the company's stock valued at $5,178,000 after buying an additional 642,830 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Trevi Therapeutics by 31.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,143 shares of the company's stock valued at $278,000 after buying an additional 10,445 shares during the last quarter. AQR Capital Management LLC boosted its position in Trevi Therapeutics by 20.4% in the 1st quarter. AQR Capital Management LLC now owns 27,720 shares of the company's stock valued at $174,000 after buying an additional 4,688 shares during the last quarter. MPM Bioimpact LLC boosted its position in Trevi Therapeutics by 10.8% in the 1st quarter. MPM Bioimpact LLC now owns 3,428,366 shares of the company's stock valued at $21,564,000 after buying an additional 333,470 shares during the last quarter. Finally, Braidwell LP bought a new position in Trevi Therapeutics in the 1st quarter valued at $453,000. 95.76% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

TRVI has been the topic of a number of analyst reports. D. Boral Capital reissued a "buy" rating and issued a $21.00 price target on shares of Trevi Therapeutics in a research note on Monday, June 2nd. Oppenheimer reissued an "outperform" rating on shares of Trevi Therapeutics in a research note on Monday, June 2nd. Cantor Fitzgerald initiated coverage on Trevi Therapeutics in a research note on Tuesday, July 1st. They issued an "overweight" rating and a $25.00 price target on the stock. Raymond James Financial cut their price target on Trevi Therapeutics from $29.00 to $27.00 and set a "strong-buy" rating on the stock in a research note on Friday, August 8th. Finally, HC Wainwright initiated coverage on Trevi Therapeutics in a research note on Wednesday, May 28th. They issued a "buy" rating and a $21.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the company's stock. Based on data from MarketBeat.com, Trevi Therapeutics currently has an average rating of "Buy" and a consensus price target of $21.75.

Trevi Therapeutics Stock Up 1.3%

Trevi Therapeutics stock traded up $0.12 during mid-day trading on Thursday, hitting $9.74. 4,789,866 shares of the company's stock were exchanged, compared to its average volume of 1,944,422. The firm has a market capitalization of $1.19 billion, a P/E ratio of -23.19 and a beta of 0.71. Trevi Therapeutics, Inc. has a fifty-two week low of $2.36 and a fifty-two week high of $9.92. The company's 50 day simple moving average is $7.24 and its 200-day simple moving average is $6.45.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.01. Research analysts expect that Trevi Therapeutics, Inc. will post -0.49 EPS for the current year.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.